本帖最后由 老马 于 2013-3-13 13:43 编辑 4 c2 @+ G5 @' h
$ k5 m' k- ?7 t& n- k健择（吉西他滨）+顺铂+阿瓦斯汀3 k( A+ @# l+ K8 u4 e
Gemzar +Cisplatin + Avastin! P. H/ M% G" g; I$ f2 B1 k! z
http://annonc.oxfordjournals.org/content/21/9/1804.full% o4 y. n. o4 e) j( K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) & I( _2 F3 b1 x' w9 X/ C& g2 ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ X/ W. y: C5 j6 Q# A+ W6 H. cResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ( m7 d8 z' O: Q |" Y% G7 ]8 X
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 789)
/ D, P9 | A+ t& w2 d& P华为网盘附件：6 E; k0 @; c- }. n6 u
【华为网盘】ava.JPG* L* N# Q$ `+ S; U+ P5 \
|
显身卡
